Next-Generation Psychedelic Drug Development
Lindsay P. Cameron, Matthew W. Johnson, Kevin S. Murnane, M. Rasenick, Charles D. Nichols
ACS Chemical Neuroscience September 15, 2026 DOI: 10.1021/acschemneuro.6c00492 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | The authors review assays and models used in psychedelic drug development, weighing their strengths and limitations, and propose guidance for developing next-generation psychedelic therapies for neuropsychiatric disorders including depression, anxiety, and post-traumatic stress disorder. |
Abstract
Psychedelic medicine has gained rapid popularity for the treatment of a variety of neuropsychiatric disorders, including depression, anxiety, and post-traumatic stress disorder. As novel psychedelic analogues and treatment regimes emerge, increasing numbers of variables are being tested. Here, we review various approaches and considerations for novel psychedelic therapies, including the strengths and limitations of current assays and models. Finally, we provide guidance and considerations for next-generation psychedelic drug development.
Citations in the library
Cites 92
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action Neuroreport December 1, 1998
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
and 87 more in the library